Patents Examined by Amanda Shaw
-
Patent number: 8222389Abstract: The present invention relates to the use in a diagnostic hybridization assay of a molecular beacon probe for lowering: the effect of sequence variations in a nucleic acid analyte, and/or the IBL effect due to the possible opening of the stem-loop structure of a molecular beacon by way of (contaminants in the amplification) enzymes, which assay comprises the steps of contacting a set of primers and a sample containing the nucleic acid analyte to amplify the analyte and detecting the amplified analyte or its complement using a molecular beacon probe, wherein the molecular beacon probe comprises one or more nucleotides and/or nucleotide analogues that have an affinity increasing modification. The invention also relates to such molecular beacon probe and to a kit for performing a diagnostic assay using such molecular beacon probe.Type: GrantFiled: December 2, 2003Date of Patent: July 17, 2012Assignee: Biomerieux B.V.Inventor: Fokke Venema
-
Patent number: 8216787Abstract: Methods and compositions for determining whether a subject will age without developing cognitive decline are provided. An exemplary method includes detecting one or more allelic variants in a gene encoding low density lipoprotein-related protein 1B. In a preferred embodiment, the detecting step is accomplished by contacting a sample obtained from the subject with a probe that forms a detectable complex with a nucleic acid in the sample containing an allelic variant indicative of aging without developing cognitive decline, wherein detection of the allelic variant in the sample indicates that the subject will age without developing cognitive decline.Type: GrantFiled: April 14, 2010Date of Patent: July 10, 2012Assignee: Medical College of Georgia Research Institute, Inc.Inventor: Shirley E. Poduslo
-
Patent number: 8206925Abstract: There is disclosed the cloning and identification of human IL-23R splice variants caused by alternative splicing of the IL-23R mRNA in human. Alternative mRNA forms occur through skipping one, multiple full exons or partial exons, within the IL-23R gene. A total of twenty-five (25) different IL-23R transcripts were identified. A novel exon deletion (exon 9) isoform in the interleukin 23 receptor is disclosed, denoted as ?9. The present application also describes a quantitative assay to measure different IL-23R isoform. Detection of ?9 isoform of IL-23R is predominantly present in colon and cervical tissues. A decrease in ?9 is observed in inflamed colon tissues in Crohn's patients. There is disclosed a method of predicting Crohn's disease by measuring ?9 isoform of IL-23R.Type: GrantFiled: April 14, 2009Date of Patent: June 26, 2012Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Shih-hsin Kan, Giacomo Mancini
-
Patent number: 8207323Abstract: A nanoscale motion detector attaches a gold nanorod (30) to the rotating arm (26) of a molecular structure (10) to cause the nanoparticle to rotate. The molecular structure is an F1-ATPase enzyme. The gold nanorod is exposed to a light source. The long axis of the gold nanorod scatters red light when the nanorod is in a first position. The short axis of the gold nanorod scatters green light when the nanorod is in a second position. A polarizing filter filters the red and green light to detect the rotational motion by observing alternating red and green lights. A detection DNA stand (50) is coupled between the gold nanorod and the molecular structure. The detection DNA strand hybridizes with a target DNA strand (58) if the target DNA strand matches the detection DNA strand to form a structural link between the molecular structure and gold nanorod.Type: GrantFiled: May 9, 2011Date of Patent: June 26, 2012Assignee: Arizonia Board of Regents for and on Behalf of Arizonia State UniversityInventors: Wayne D. Frasch, Lars Chapsky
-
Patent number: 8192936Abstract: A nanoscale motion detector attaches a gold nanorod (30) to the rotating arm (26) of a molecular structure (10) to cause the nanoparticle to rotate. The molecular structure is an F1-ATPase enzyme. The gold nanorod is exposed to a light source. The long axis of the gold nanorod scatters red light when the nanorod is in a first position. The short axis of the gold nanorod scatters green light when the nanorod is in a second position. A polarizing filter filters the red and green light to detect the rotational motion by observing alternating red and green lights. A detection DNA stand (50) is coupled between the gold nanorod and the molecular structure. The detection DNA strand hybridizes with a target DNA strand (58) if the target DNA strand matches the detection DNA strand to form a structural link between the molecular structure and gold nanorod.Type: GrantFiled: May 9, 2011Date of Patent: June 5, 2012Assignee: Arizona Board of Regents for and on behalf of Arizona State UniversityInventors: Wayne D. Frasch, Lars Chapsky
-
Patent number: 8187809Abstract: The present invention provides a novel marker capable of accurately diagnosing the lymph node metastasis of stomach cancer. An mRNA, or a fragment thereof, coding for at least one protein selected from TFF1, AGR2, PRSS8, MUC1, MUC4 and MUC17 can be useful as a lymph node metastasis marker.Type: GrantFiled: January 11, 2008Date of Patent: May 29, 2012Assignee: Sysmex CorporationInventors: Hideki Takata, Takayuki Takahata, Kazuki Nakabayashi, Kayo Shoji, Yasuhiro Otomo
-
Patent number: 8182990Abstract: Disclosed is a set of genetic polymorphisms linked to optic neuropathy including glaucoma and Leber's disease. Those polymorphisms are useful for diagnosing and predicting susceptibility to optic neuropathy.Type: GrantFiled: March 18, 2005Date of Patent: May 22, 2012Assignee: Rusk Intellectual Reserve AGInventor: Yukihiko Mashima
-
Patent number: 8148076Abstract: The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.Type: GrantFiled: June 1, 2011Date of Patent: April 3, 2012Assignee: Genomic Health, Inc.Inventors: Joffre B. Baker, Maureen T. Cronin, Steven Shak, Jose Baselga
-
Patent number: 8137915Abstract: The invention concerns genes involved in inflammatory and/or immune diseases and some cancers, in particular intestinal cryptogenic inflammatory diseases, and proteins coded by these genes. The invention also concerns methods for diagnosing inflammatory diseases.Type: GrantFiled: February 12, 2009Date of Patent: March 20, 2012Assignee: Fondation Jean Dausset-CEPHInventors: Jean Pierre Hugot, Gilles Thomas, Mohamed Zouali, Suzanne Lesage, Mathias Chamaillard
-
Patent number: 8137916Abstract: The invention relates to genetic screens for susceptibility to Alzheimer's disease. In particular, the invention provides genetic screens based on genotyping of the p21E2c31 C/A polymorphism and/or the p21E3+20 C/T polymorphism in the p21cip 1 gene.Type: GrantFiled: October 26, 2010Date of Patent: March 20, 2012Assignee: Isis Innovation Ltd.Inventor: Zsuzsanna Nagy
-
Patent number: 8124345Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.Type: GrantFiled: July 30, 2010Date of Patent: February 28, 2012Assignee: Quest Diagnostics Investments IncorporatedInventors: Weimin Sun, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
-
Patent number: 8105780Abstract: There is provided a resonator sensor useful for detecting polymorphisms and mutations in DNA. The resonator sensor has a capture molecule immobilised on its surface, the capture molecule being either a probe DNA containing a reference sequence, or a mismatch binding molecule, and being capable of forming a probe DNA/target DNA/mismatch binding molecule complex on the surface of the resonator. A method for detecting mutations in a target DNA, including single nucleotide polymorphisms, is also provided.Type: GrantFiled: September 22, 2004Date of Patent: January 31, 2012Assignees: Agency for Science, Technology and Research, National University of SingaporeInventors: Xiaodi Su, Rudolf Robelek, Wolfgang Knoll, Sean O'Shea
-
Patent number: 8105781Abstract: The present invention relates, in general, to perioperative depression and, in particular, to methods of identifying individuals at risk of perioperative depression.Type: GrantFiled: October 14, 2008Date of Patent: January 31, 2012Assignee: Duke UniversityInventors: Mihal V. Podgoreanu, Joseph P. Mathew, Robert L. Lobato, Mark F. Newman, Mark Stafford-Smith, William D. White
-
Patent number: 8084198Abstract: The use of the single nucleotide polymorphism (SNP) at position ?(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined.Type: GrantFiled: May 3, 2006Date of Patent: December 27, 2011Assignee: Sanofi-AventisInventors: Detlef Kozian, Matthias Herrmann, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace
-
Patent number: 8080371Abstract: Correlations between polymorphisms and addiction are provided. Methods of diagnosing, prognosing, and treating addiction are provided. Systems and kits for diagnosis, prognosis and treatment of addiction are provided. Methods of identifying addiction modulators are also described.Type: GrantFiled: March 1, 2007Date of Patent: December 20, 2011Assignee: The Washington UniversityInventors: Dennis Ballinger, Karel Konvicka, Laura Jean Bierut, John Rice, Frank Scott Saccone, Anthony L. Hinrichs, Alison M. Goate, Jen Wang
-
Patent number: 8071286Abstract: The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.Type: GrantFiled: June 9, 2006Date of Patent: December 6, 2011Assignee: Genomic Health, Inc.Inventors: Joffre B. Baker, Maureen T. Cronin, Michael C. Kiefer, Steve Shak, Michael Graham Walker
-
Patent number: 8008003Abstract: The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.Type: GrantFiled: November 14, 2003Date of Patent: August 30, 2011Assignee: Genomic Health, Inc.Inventors: Joffre B. Baker, Maureen T. Cronin, Steve Shak, Jose Baselga
-
Patent number: 8008015Abstract: Methods and kits for diagnosing the risk of developing restenosis after revascularization by implantation of stents based on the detection of single-nucleotide polymorphisms (SNPs).Type: GrantFiled: February 24, 2009Date of Patent: August 30, 2011Assignee: Fina Biotech, S.L.U.Inventors: Vicente Andres Garcia, Carlos Silvestre Roig, Patricia Fernandez Ferri, Pedro Luis Sanchez Fernandez, Francisco Fernandez Aviles, Felipe Javier Chaves Martinez
-
Patent number: 8003316Abstract: A nanoscale motion detector attaches a gold nanorod (30) to the rotating arm (26) of a molecular structure (10) to cause the nanoparticle to rotate. The molecular structure is an F1-ATPase enzyme. The gold nanorod is exposed to a light source. The long axis of the gold nanorod scatters red light when the nanorod is in a first position. The short axis of the gold nanorod scatters green light when the nanorod is in a second position. A polarizing filter filters the red and green light to detect the rotational motion by observing alternating red and green lights. A detection DNA stand (50) is coupled between the gold nanorod and the molecular structure. The detection DNA strand hybridizes with a target DNA strand (58) if the target DNA strand matches the detection DNA strand to form a structural link between the molecular structure and gold nanorod.Type: GrantFiled: December 11, 2003Date of Patent: August 23, 2011Assignee: Arizona Board of Regents, Acting for and on Behalf of Arizona State UniversityInventors: Wayne D. Frasch, Lars Chapsky
-
Patent number: 8003318Abstract: The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of a single nucleotide polymorphisms (SNPs) within the bovine genes encoding growth hormone receptor (GHR), ghrelin, leptin, neuropeptide Y (NPY), and Uncoupling Protein 2 (UCP2) and their association with economically relevant traits in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.Type: GrantFiled: January 16, 2007Date of Patent: August 23, 2011Assignee: The Governors of the University of AlbertaInventors: Stephen Moore, Donald Joshua Nkrumah, Esther Laura Sherman